Overall, DSIP emerges as a biologically significant peptide with broad medical promise
2.1% (consistent with weight loss rate) No Safety Signals: No increased risk of pancreatitis, thyroid tumors, or major CV events Historic Achievement: REDEFINE-1 demonstrated that CagriSema produces the highest mean weight loss (22.7%) ever reported for an obesity pharmacotherapy in a Phase 3 trial
Wegovy is an FDA-approved medication primarily used for the treatment of: Chronic weight management in adults who are overweight or obese Weight-related health conditions such as high blood pressure, type 2 diabetes, and high cholesterol
Compounded Tirzepatide *Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality
Educate about possible side effects (leg swelling, headache)
Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study